1 completed, 1 enrolling by invitation, 1 recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 1, Enrolling by invitation 1, Recruiting 1 |
Follow Steinert Disease: new trials by email Literature Review of Steinert Disease trials Research Report on Steinert Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1 zeleciment basivarsen (DYNE-101), Placebo - Myotonic Dystrophy Type 1 (DM1), DM1 | Phase 3 | Recruiting | Dyne Therapeutics | 150 | 2026-05-14 | 2026-10-13 |
| Global Open-Label Extension Study of Del-desiran for the Treatment of DM1 Del-desiran (AOC 1001) - Myotonic Dystrophy Type 1, DM1 | Phase 3 | Enrolling by invitation | Avidity Biosciences, Inc. | 199 | 2025-06-26 | 2026-08-19 |
| Global Study of Del-desiran for the Treatment of DM1 AOC 1001 (del-desiran), Placebo - DM1, Myotonic Dystrophy | Phase 3 | Completed | Avidity Biosciences, Inc. | 159 | 2024-05-30 | 2026-09-01 |
Myotonia (3) · Myotonic Disorders (3) · Myotonic Dystrophy (3)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Genetic Diseases, Inborn (3) · Heredodegenerative Disorders, Nervous System (3) · Muscular Diseases (3) · Muscular Disorders, Atrophic (3) · Muscular Dystrophies (3) · Musculoskeletal Diseases (3) · Nervous System Diseases (3) · Neurodegenerative Diseases (3) · Neurologic Manifestations (3) · Neuromuscular Diseases (3) · Neuromuscular Manifestations (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3)
Avidity Biosciences, Inc. (2) · Dyne Therapeutics (1)
Denmark (3) · France (3) · Germany (3) · Italy (3) · Japan (3) · Netherlands (3) · Spain (3) · United Kingdom (3) · United States (3) · Canada (2) · Australia (1) · Belgium (1)
2025 (1)